A short history of TB-500

TB-500 is the grey-market label most commonly used for a synthetic version of thymosin beta-4, a 43-amino-acid peptide that was first isolated and sequenced from calf thymus tissue in 1981^[1]. The arc from that biochemistry paper to today's sports-drug bans and nascent human trials spans four decades and touches on immunology, cardiac research, anti-doping enforcement, and one small but rigorous Phase III eye study. Here is that timeline, milestone by milestone.

1960s to 1981: discovery of thymosin fraction 5 and sequencing of beta-4

The story begins in the laboratory of Allan Goldstein at the Albert Einstein College of Medicine, where researchers in the late 1960s and early 1970s isolated a mixture of small proteins from calf thymus gland and called it thymosin fraction 5. The fraction attracted interest because it appeared to restore immune function in thymus-deprived animals. Within that mixture was a 43-residue peptide that would later be called thymosin beta-4.

In 1981, Tung-Leung Low, Su-Kuei Hu, and Allan Goldstein published the complete amino acid sequence of bovine thymosin beta-4 in the Proceedings of the National Academy of Sciences^[1]. They found that the N-terminus was blocked by an acetyl group and that the peptide could induce terminal deoxynucleotidyl transferase activity in mouse thymocytes, a marker of early lymphocyte development. That sequence paper, PMID 6940133, became the structural foundation for everything that followed.

1990s to 2005: from immune peptide to tissue-repair candidate

For about a decade after sequencing, thymosin beta-4 was studied mainly as an immune modulator. The framing shifted in the late 1990s when researchers discovered that its primary physiological role was G-actin sequestration: the peptide binds to unpolymerised actin monomers and regulates the actin cytoskeleton in virtually every mammalian cell type.

A 2005 review in Trends in Molecular Medicine by Goldstein, Hannappel, and Kleinman described how thymosin beta-4's actin-binding function positioned it as a tissue-repair agent^[2]. The authors documented wound-healing effects in dermal and corneal injury models and proposed potential uses after cardiac hypoxia. By then the peptide had a second career as a preclinical regenerative compound, quite separate from its original immunological framing.

Animal studies across this period covered a wide range of models. A 2010 review by Philp and Kleinman in the Annals of the New York Academy of Sciences catalogued evidence from dermal, corneal, and cardiac wound models^[3]. Proposed mechanisms included down-regulation of inflammatory chemokines, promotion of cell migration, new blood-vessel formation, and stem-cell maturation.

2010s: cardiac research and the TB-500 label

A parallel thread ran through cardiac biology from around 2010. The peptide received significant attention as a potential heart-repair agent after myocardial infarction, with reviews in journals including Expert Opinion on Biological Therapy and Current Medicinal Chemistry summarising preclinical data in heart-injury models^[4]. None of this preclinical work produced an approved cardiac medicine.

It was during this period that the label "TB-500" entered online fitness and self-experimentation communities. The name technically refers to the heptapeptide AC-LKKTETQ (amino acids 17 to 23 of thymosin beta-4, CAS 885340-08-9), but vendors and users apply it loosely to either the short fragment or the full 43-residue peptide. The distinction matters because the two compounds have different structures and different published research profiles, yet are sold interchangeably in grey-market contexts.

2018: WADA adds TB-500 to the Prohibited List under S2

In 2018 the World Anti-Doping Agency added thymosin beta-4 and its derivatives, naming TB-500 as an example, to the Prohibited List under category S2.3 (growth factors and growth-factor modulators)^[5]. The prohibition applies both in competition and out of competition. Athletes subject to the WADA Code who test positive or are found in possession face the standard consequences under their sport's anti-doping rules.

The WADA classification reflected a broader pattern: the agency added peptide hormones and growth factors aggressively in the 2010s as sports authorities recognised that research chemicals were moving from lab benches to athlete training regimens with little or no clinical data on safety or performance effects. For current country-by-country regulatory status, see the TB-500 regulation section.

2022 to 2023: the only Western-standard human trial data

The most rigorous human trial data on any thymosin beta-4 preparation comes from ophthalmology, not sports medicine or musculoskeletal repair. RegeneRx Biopharmaceuticals ran a randomised, placebo-controlled, double-masked Phase III trial of RGN-259, a 0.1% thymosin beta-4 ophthalmic solution, in patients with neurotrophic keratopathy (stages 2 and 3), a condition where corneal nerves are damaged and the epithelium fails to heal^[6].

Published in the International Journal of Molecular Sciences in 2022 (PMID 36613994), the trial found that 60 per cent of treated patients achieved complete healing within four weeks compared with 12.5 per cent receiving placebo. No significant adverse effects were observed. The study used a topical ophthalmic preparation, a different route and formulation from the subcutaneous injections sold in grey-market contexts. It has not been approved by the FDA or EMA as of mid-2026, though RegeneRx continued regulatory discussions.

Current status: not approved anywhere, PCAC review pending

As of July 2026, thymosin beta-4 and TB-500 hold no marketing authorisation from the FDA, EMA, MHRA, or any of the other national agencies in the countries PeptideMethods covers. In all seven jurisdictions it sits in the grey-market category: not an approved medicine, not explicitly scheduled as a controlled substance in most places, but also not lawfully sold for human use.

The FDA's Pharmacy Compounding Advisory Committee is scheduled to review thymosin beta-4 preparations for the 503A bulk-drug-substances list in 2026. That review addresses whether US compounding pharmacies may legally prepare the peptide; it is not a path to marketing authorisation and will not produce an approved medicine regardless of outcome. The compound remains WADA-prohibited under S2 for all athletes subject to the WADA Code^[5].

What we still do not know

Four decades of preclinical work have not translated into a single approved therapeutic use for the full-length thymosin beta-4 or the TB-500 fragment in any systemic indication. The RGN-259 ophthalmic data^[6] is the closest the field has come to a controlled human trial, and it covers a very specific topical application.

The core gaps are: no Phase II or Phase III randomised controlled trial for musculoskeletal, cardiac, or general tissue-repair indications; no validated dosing regimen for any systemic use; no published pharmacokinetic data from subcutaneous injection in healthy adults outside of limited early-phase work; and no long-term safety data. The 2010 Crockford review noted that clinical investigations were ongoing in dermal, corneal, and cardiac repair^[4], but fifteen years later only the corneal work has produced Phase III data.

For the full picture of TB-500's mechanism, regulatory status by country, and the preclinical evidence in context, see the TB-500 peptide page.